Patents by Inventor Tetsuhiko Yoshida

Tetsuhiko Yoshida has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11324831
    Abstract: Provided is a novel material used to introduce an exogenous substance into cells. Also provided is a method for introducing an exogenous substance into target cells using this material. The present invention provides an exosome that is used to introduce an exogenous substance into target cells, wherein the exosome contains one type or two or more types of an exogenous substance and a substance that induces macropinocytosis in the target cells. The present invention also provides a composition containing the exosome and a method for introducing an exogenous substance into cells using this exosome.
    Type: Grant
    Filed: May 3, 2017
    Date of Patent: May 10, 2022
    Inventors: Ikuhiko Nakase, Tetsuhiko Yoshida, Nahoko Baileykobayashi
  • Patent number: 11313862
    Abstract: The method for aiding ALS detection provided by the present invention includes determining a profile of signal peptides contained in a bodily fluid from a test subject, and comparing the signal peptide profile thus determined for the test subject with a previously-determined profile of signal peptides in a bodily fluid from a healthy subject. The presence of a difference between the signal peptide profile of the test subject and the signal peptide profile of the healthy subject at a specific molecular weight is then associated with the test subject's suffering from or developing ALS.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: April 26, 2022
    Assignees: Toagosei Co., Ltd., National University Corporation Nagoya University
    Inventors: Nahoko Baileykobayashi, Makoto Sawada, Tetsuhiko Yoshida
  • Patent number: 11299555
    Abstract: This method for aiding Alzheimer's detection provided by the present invention includes: determining a profile of signal peptides contained in a bodily fluid from a test subject, and comparing the signal peptide profile thus determined for the test subject with a previously-determined profile of signal peptides in a bodily fluid from a healthy subject. A difference between the signal peptide profile of the test subject and the signal peptide profile of the healthy subject at a specific molecular weight is then associated with the test subject's suffering from or developing Alzheimer's.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: April 12, 2022
    Assignees: Toagosei Co., LTD, National University Corporation Nagoya University
    Inventors: Nahoko Baileykobayashi, Makoto Sawada, Tetsuhiko Yoshida
  • Patent number: 11285195
    Abstract: The pharmaceutical composition for inhibiting expression of CD47 in tumor cells provided by the present invention contains: exosomes produced by cultured tumor cells in an amount effective for inhibiting expression of the CD47; and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: March 29, 2022
    Inventors: Ikuhiko Nakase, Kosuke Noguchi, Nahoko Baileykobayashi, Tetsuhiko Yoshida
  • Publication number: 20220089641
    Abstract: The disclosure provides a technology for efficiently introducing a foreign substance into at least cytoplasm of eukaryotic cells from outside the cells. The method disclosed here for introducing a foreign substance of interest in vitro or in vivo into at least cytoplasm of eukaryotic cells from outside the cells includes (1) a step of preparing a foreign substance introduction construct including a carrier fragment composed of KKRTLRKSNRKKR (SEQ ID NO:1) and the foreign substance of interest linked to the N-terminal and/or C-terminal side of the carrier peptide fragment; (2) a step of supplying the foreign substance introduction construct to a sample containing a target eukaryotic cell; and (3) a step of incubating the sample, to which the foreign substance introduction construct has been supplied, to thereby introduce the construct into the eukaryotic cell in the sample.
    Type: Application
    Filed: September 10, 2021
    Publication date: March 24, 2022
    Inventors: Nahoko Baileykobayashi, Tetsuhiko Yoshida
  • Patent number: 11230586
    Abstract: The method of producing induced lightweight exosomes (iLE) provided by the present invention includes preparing a cell culture containing prescribed cultured cells; supplying at least once an artificially produced synthetic peptide to the cell culture and culturing the cell culture for a prescribed interval; and obtaining exosomes produced by the cultured cells following culturing. Here, the synthetic peptide is provided with: (1) an exosome-inducing peptide sequence and (2) a CPP sequence, and has a total number of amino acid residues of 100 or less.
    Type: Grant
    Filed: January 15, 2020
    Date of Patent: January 25, 2022
    Assignees: TOAGOSEI CO., LTD, University Public Corporation Osaka
    Inventors: Nahoko Baileykobayashi, Tetsuhiko Yoshida, Ikuhiko Nakase
  • Publication number: 20220008547
    Abstract: A method of introducing a foreign substance from the outside of eukaryotic cells into at least a cytoplasm of the cells in vitro or in vivo disclosed here includes the following steps: (1) preparing a construct for introducing a foreign substance, wherein the construct includes a carrier peptide fragment composed of the following amino acid sequence: TLKERCLQVVRSLVKKKRTLRKNDRKKR (SEQ ID NO: 1), and the foreign substance bound to an N-terminal side and/or C-terminal side of the carrier peptide fragment; (2) supplying the construct into a sample containing target eukaryotic cells; and (3) incubating the sample to which the construct is supplied, wherein the construct is introduced into the target eukaryotic cells in the sample.
    Type: Application
    Filed: June 29, 2021
    Publication date: January 13, 2022
    Inventors: Nahoko Baileykobayashi, Tetsuhiko Yoshida
  • Publication number: 20210380642
    Abstract: The synthetic peptide disclosed here includes (1) an amino acid sequence represented by any of SEQ ID NOS:1 to 10, or a modified amino sequence formed by deletion, substitution or addition of 1, 2 or 3 amino acid residues in any of these amino acid sequences, together with (2) an amino acid sequence (CPP sequence) that functions as a cell penetrating peptide (CPP), and consists of a total of not more than 100 amino acid residues.
    Type: Application
    Filed: May 25, 2021
    Publication date: December 9, 2021
    Inventors: Tetsuhiko Yoshida, Ayato Takada, Nahoko Baileykobayashi
  • Patent number: 11155582
    Abstract: An antiviral peptide provided according to the present invention includes (1) an amino acid sequence (TM sequence) constituting a transmembrane region of G protein of vesicular stomatitis virus (VSV) or a modified amino acid sequence formed by conservative substitutions of 1, 2, or 3 amino acid residues in the TM sequence; and (2) an amino acid sequence (CPP sequence) functioning as a cell penetrating peptide (CPP), wherein a total number of amino acid residues is 100 or less.
    Type: Grant
    Filed: October 3, 2019
    Date of Patent: October 26, 2021
    Assignees: TOAGOSEI CO., LTD, National University Corporation Hokkaido University
    Inventors: Tetsuhiko Yoshida, Ayato Takada, Nahoko Baileykobayashi
  • Publication number: 20210238251
    Abstract: The synthetic peptide disclosed herein is a synthetic peptide which is artificially synthesized for suppressing binding of CTLA4 to at least one of B7 proteins B7-1 and B7-2. The synthetic peptide includes a CTLA4-B7 protein binding inhibitory peptide sequence. The CTLA4-B7 protein binding inhibitory peptide sequence is any one of amino acid sequences shown in the following (1) to (3): (1) a TIM3-SP-related sequence; (2) an LAG3-SP-related sequence; and (3) a CTLA4-SP-related sequence. Here, the total number of amino acid residues in the above-described synthetic peptide is 100 or less.
    Type: Application
    Filed: December 9, 2020
    Publication date: August 5, 2021
    Inventors: Nahoko Baileykobayashi, Tetsuhiko Yoshida
  • Publication number: 20210115089
    Abstract: A synthetic peptide provided by the present invention includes: (1) a CTLA4-SP-related sequence; and (2) an amino acid sequence that functions as a cell penetrating peptide, wherein the synthetic peptide has a total number of amino acid residues of 100 or less.
    Type: Application
    Filed: October 8, 2020
    Publication date: April 22, 2021
    Inventors: Nahoko Baileykobayashi, Tetsuhiko Yoshida, Shuichi Asakawa
  • Patent number: 10981953
    Abstract: A method for promoting expression of calreticulin in at least one kind of eukaryotic cell, and a synthetic peptide useful in this method are provided. In the method provided by the present invention, a culture of target cells is prepared, and a calreticulin expression-promoting peptide having calreticulin expression-promoting activity is supplied at least once to that culture.
    Type: Grant
    Filed: December 24, 2014
    Date of Patent: April 20, 2021
    Assignees: TOAGOSEI CO, LTD., KYOTO UNIVERSITY
    Inventors: Nahoko Baileykobayashi, Tetsuhiko Yoshida, Yoshinori Yoshida, Kazuhisa Chonabayashi
  • Publication number: 20200407412
    Abstract: A synthetic peptide provided according to the technology disclosed here includes (1) a CMTM4-TM related sequence; and (2) an amino acid sequence that functions as cell membrane permeable peptide. The synthetic peptide has a total number of amino acid residues of 100 or less.
    Type: Application
    Filed: June 1, 2020
    Publication date: December 31, 2020
    Inventors: Nahoko Baileykobayashi, Tetsuhiko Yoshida
  • Patent number: 10829523
    Abstract: The anti-tumor peptide provided by the present invention is a synthetic peptide having both amino acid sequences represented by the following (1) and (2): (1) an amino acid sequence constituting the transmembrane domain of transmembrane protein 141 (TMEM 141), or a modified amino acid sequence having deletion, replacement, or addition of one, two, or three amino acid residues of the amino acid sequence; and (2) an amino acid sequence functioning as a cell membrane penetrating peptide (CPP).
    Type: Grant
    Filed: November 16, 2017
    Date of Patent: November 10, 2020
    Assignees: Keio University, National University Corporation Nagoya, Toagosei Co., Ltd.
    Inventors: Nahoko Baileykobayashi, Tetsuhiko Yoshida, Makoto Sawada, Jun Kudoh, Tamami Adachi, Yasuhiro Tonoyama
  • Patent number: 10745448
    Abstract: An antiviral peptide provided by the present invention includes: (1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (2) an amino acid sequence that functions as a cell penetrating peptide (CPP).
    Type: Grant
    Filed: October 2, 2018
    Date of Patent: August 18, 2020
    Assignee: Toagosei Co., LTD
    Inventors: Tetsuhiko Yoshida, Ayato Takada, Nahoko Baileykobayashi
  • Publication number: 20200231647
    Abstract: The method of producing induced lightweight exosomes (iLE) provided by the present invention includes preparing a cell culture containing prescribed cultured cells; supplying at least once an artificially produced synthetic peptide to the cell culture and culturing the cell culture for a prescribed interval; and obtaining exosomes produced by the cultured cells following culturing. Here, the synthetic peptide is provided with: (1) an exosome-inducing peptide sequence and (2) a CPP sequence, and has a total number of amino acid residues of 100 or less.
    Type: Application
    Filed: January 15, 2020
    Publication date: July 23, 2020
    Inventors: Nahoko Baileykobayashi, Tetsuhiko Yoshida, Ikuhiko Nakase
  • Publication number: 20200148740
    Abstract: An antitumor peptide provided according to the present invention includes (1) an S1PR-TM related sequence; and (2) an amino acid sequence functioning as a cell penetrating peptide; wherein the total number of amino acid residues is 100 or less.
    Type: Application
    Filed: October 28, 2019
    Publication date: May 14, 2020
    Inventors: Nahoko Baileykobayashi, Tetsuhiko Yoshida, Makoto Sawada
  • Publication number: 20200109177
    Abstract: An antiviral peptide provided according to the present invention includes (1) an amino acid sequence (TM sequence) constituting a transmembrane region of G protein of vesicular stomatitis virus (VSV) or a modified amino acid sequence formed by conservative substitutions of 1, 2, or 3 amino acid residues in the TM sequence; and (2) an amino acid sequence (CPP sequence) functioning as a cell penetrating peptide (CPP), wherein a total number of amino acid residues is 100 or less.
    Type: Application
    Filed: October 3, 2019
    Publication date: April 9, 2020
    Inventors: Tetsuhiko Yoshida, Ayato Takada, Nahoko Baileykobayashi
  • Publication number: 20200055915
    Abstract: Provide is an artificially synthesized antitumor peptide that may suppress proliferation of tumor cells. The peptide provided is a synthetic peptide that contains both (1) an amino acid sequence that forms a signal peptide of a membrane protein, programmed cell death-1 (PD-1), or a modified amino acid sequence thereof in which 1, 2 or 3 amino acid residues deleted from, substituted in or added to the above amino acid sequence; and (2) an amino acid sequence that serves as a cell penetrating peptide (CPP), and wherein the synthetic peptide comprises a total of 100 or fewer amino acid residues.
    Type: Application
    Filed: March 27, 2018
    Publication date: February 20, 2020
    Inventors: Makoto SAWADA, Nahoko BAILEYKOBAYASHI, Tetsuhiko YOSHIDA
  • Publication number: 20200031902
    Abstract: The antitumor peptide provided by the present invention is a synthetic peptide including both of: (1) an amino acid sequence composing the second transmembrane region from the N-terminal of a membrane protein sphingosine 1-phosphate receptor 1 (S1PR1), or a modified amino acid sequence formed by deletion substitution or addition of 1, 2 or 3 amino acid residues in the amino acid sequence; and (2) an amino acid sequence functioning as a cell-penetrating peptide (CPP); wherein the total number of amino acid residues is 100 or less.
    Type: Application
    Filed: July 30, 2019
    Publication date: January 30, 2020
    Inventors: Nahoko BAILEYKOBAYASHI, Tetsuhiko YOSHIDA, Makoto SAWADA